Continued Evaluation of Patients With Parkinson's Disease Who Previously Received BRT-DA01
Sponsored by BlueRock Therapeutics
About this trial
Last updated a year ago
Study ID
BRT-DA01-501
Status
Enrolling by invitation
Type
Observational
Placebo
No
Accepting
50 to 78 Years
All
Not accepting
Healthy Volunteers
Trial Timing
Started 2 years ago
What is this trial about?
This is a multicenter study to evaluate the safety and clinical outcomes of BRT-DA01 in
subjects with PD who previously received BRT-DA01 in the Phase 1 Study MSK-DA01-101.No
investigational therapy will be administered in this study.
What are the participation requirements?
Inclusion Criteria
- Subject received BRT-DA01 in Study MSK-DA01-101 (ie, parent study) and will have completed or discontinued the parent study
- Subject must be willing and able to provide written informed consent for the BRT-DA0-501 study in accordance with applicable regulations and guidelines and to comply with all study visits and procedures
Exclusion Criteria
- No exclusion criteria